Is Sangani Hospital overvalued or undervalued?

As of 29 August 2025, Sangani Hospital's valuation grade has moved from fair to attractive, indicating a more favorable outlook. The company is currently considered undervalued, with a PE ratio of 35.59, an EV to EBITDA of 29.71, and a ROCE of 12.91%. In comparison to its peers, Sangani Hospital's valuation metrics stand out; for instance, Max Healthcare is classified as very expensive with a PE of 92.6, while Apollo Hospitals, also attractive, has a PE of 69.47.
Despite a recent dip in stock price, Sangani Hospital has shown strong performance over the past year with a return of 59.29%, significantly outperforming the Sensex, which returned -2.88% in the same period. This reinforces the notion that Sangani Hospital is undervalued relative to its growth potential and industry peers.